Literature DB >> 28144841

Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models.

Elham Haem1,2, Kajsa Harling2, Seyyed Mohammad Taghi Ayatollahi1, Najaf Zare3, Mats O Karlsson2.   

Abstract

One important aim in population pharmacokinetics (PK) and pharmacodynamics is identification and quantification of the relationships between the parameters and covariates. Lasso has been suggested as a technique for simultaneous estimation and covariate selection. In linear regression, it has been shown that Lasso possesses no oracle properties, which means it asymptotically performs as though the true underlying model was given in advance. Adaptive Lasso (ALasso) with appropriate initial weights is claimed to possess oracle properties; however, it can lead to poor predictive performance when there is multicollinearity between covariates. This simulation study implemented a new version of ALasso, called adjusted ALasso (AALasso), to take into account the ratio of the standard error of the maximum likelihood (ML) estimator to the ML coefficient as the initial weight in ALasso to deal with multicollinearity in non-linear mixed-effect models. The performance of AALasso was compared with that of ALasso and Lasso. PK data was simulated in four set-ups from a one-compartment bolus input model. Covariates were created by sampling from a multivariate standard normal distribution with no, low (0.2), moderate (0.5) or high (0.7) correlation. The true covariates influenced only clearance at different magnitudes. AALasso, ALasso and Lasso were compared in terms of mean absolute prediction error and error of the estimated covariate coefficient. The results show that AALasso performed better in small data sets, even in those in which a high correlation existed between covariates. This makes AALasso a promising method for covariate selection in nonlinear mixed-effect models.

Entities:  

Keywords:  Adaptive Lasso; Covariate model building; Lasso; Mixed effects modeling; Multicollinearity

Mesh:

Year:  2017        PMID: 28144841     DOI: 10.1007/s10928-017-9504-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  13 in total

1.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

2.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

3.  The lasso method for variable selection in the Cox model.

Authors:  R Tibshirani
Journal:  Stat Med       Date:  1997-02-28       Impact factor: 2.373

4.  Multiple single nucleotide polymorphism analysis using penalized regression in nonlinear mixed-effect pharmacokinetic models.

Authors:  Julie Bertrand; David J Balding
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

5.  Regularized estimation of large-scale gene association networks using graphical Gaussian models.

Authors:  Nicole Krämer; Juliane Schäfer; Anne-Laure Boulesteix
Journal:  BMC Bioinformatics       Date:  2009-11-24       Impact factor: 3.169

6.  Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.

Authors:  Adrien Tessier; Julie Bertrand; Marylore Chenel; Emmanuelle Comets
Journal:  AAPS J       Date:  2015-02-20       Impact factor: 4.009

7.  Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.

Authors:  F P Combes; S Retout; N Frey; F Mentré
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-09

8.  Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.

Authors:  Anne-Gaëlle Dosne; Martin Bergstrand; Kajsa Harling; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-10-11       Impact factor: 2.745

9.  Simultaneous analysis of all SNPs in genome-wide and re-sequencing association studies.

Authors:  Clive J Hoggart; John C Whittaker; Maria De Iorio; David J Balding
Journal:  PLoS Genet       Date:  2008-07-25       Impact factor: 5.917

10.  Combined Analysis of Phase I and Phase II Data to Enhance the Power of Pharmacogenetic Tests.

Authors:  A Tessier; J Bertrand; M Chenel; E Comets
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14
View more
  3 in total

1.  Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.

Authors:  Marina Senek; Dag Nyholm; Elisabet I Nielsen
Journal:  Eur J Clin Pharmacol       Date:  2018-06-07       Impact factor: 2.953

2.  A Bounded Integer Model for Rating and Composite Scale Data.

Authors:  Gustaf J Wellhagen; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

3.  Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.

Authors:  Laura B Zwep; Kevin L W Duisters; Martijn Jansen; Tingjie Guo; Jacqueline J Meulman; Parth J Upadhyay; J G Coen van Hasselt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.